Okava Pharmaceuticals
Clinical-stage veterinary biotechnology company developing pet-specific therapeutics and drug-delivery systems to extend healthy lifespan in dogs and cats. Focus areas include modified-release oral formulations for canine immune-mediated diseases and miniature subdermal implants for sustained GLP-1 delivery in cats. The company conducts preclinical and clinical studies, publishes results in peer-reviewed journals, and pursues regulatory pathways for animal drugs.
Industries
Nr. of Employees
small (1-50)
Okava Pharmaceuticals
San Francisco, California, United States, North America
Patents
Methods and compositions for delivering mycophenolic acid active agents to non-human mammals
US-11786505-B2
View DetailsMethods and compositions for delivering mycophenolic acid active agents to non-human mammals
US-11633378-B2
View Details
Methods and compositions for delivering mycophenolic acid active agents to non-human mammals
US-11786505-B2
View DetailsMethods and compositions for delivering mycophenolic acid active agents to non-human mammals
US-11633378-B2
View DetailsProducts
OKV-1001
A patented modified‑release oral formulation of mycophenolate developed for canine immune‑mediated and inflammatory conditions to improve GI tolerability, enable once‑daily dosing, and enhance efficacy compared with immediate‑release formulations.
OKV-119
A miniature, patented subdermal implant intended to provide up to six months of continuous exenatide (GLP‑1) exposure for feline weight management and diabetes management using a nanoportal controlled‑release platform.
OKV-1001
A patented modified‑release oral formulation of mycophenolate developed for canine immune‑mediated and inflammatory conditions to improve GI tolerability, enable once‑daily dosing, and enhance efficacy compared with immediate‑release formulations.
OKV-119
A miniature, patented subdermal implant intended to provide up to six months of continuous exenatide (GLP‑1) exposure for feline weight management and diabetes management using a nanoportal controlled‑release platform.
Expertise Areas
- Veterinary drug development
- Long‑acting implantable drug delivery
- Modified‑release oral formulation development
- Clinical trial design and execution in companion animals
Key Technologies
- Modified‑release oral formulations
- Subdermal implantable controlled‑release platforms
- Nano‑porous / nanoportal controlled‑release technology
- GLP‑1 (exenatide) sustained delivery
News & Updates
Publication of an open‑label, single‑arm multicentric pilot clinical study reporting reduced CADESI‑04 lesion scores in dogs with moderate‑to‑severe atopic dermatitis treated with a modified‑release mycophenolate formulation.
Publication in BMC Veterinary Research demonstrating months‑long exenatide exposure and associated weight reduction in cats using a nanoportal implant platform.
Laboratory proof‑of‑concept validation in healthy beagles showing improved efficacy and tolerability of a modified‑release mycophenolate formulation versus immediate‑release comparator.
Pilot study results on canine atopic dermatitis were selected for oral presentation at the World Congress of Veterinary Dermatology.
Received FDA Minor Use/Minor Species (MUMS) Drug Designation, making the program eligible for conditional approval and seven years of exclusive market rights.
Awarded a $500,000 FDA MUMS grant to support a prospective, randomized, placebo‑controlled multi‑site field study evaluating a modified‑release mycophenolate formulation for canine immune‑mediated hemolytic anemia.
Publication of an open‑label, single‑arm multicentric pilot clinical study reporting reduced CADESI‑04 lesion scores in dogs with moderate‑to‑severe atopic dermatitis treated with a modified‑release mycophenolate formulation.
Publication in BMC Veterinary Research demonstrating months‑long exenatide exposure and associated weight reduction in cats using a nanoportal implant platform.
Laboratory proof‑of‑concept validation in healthy beagles showing improved efficacy and tolerability of a modified‑release mycophenolate formulation versus immediate‑release comparator.
Pilot study results on canine atopic dermatitis were selected for oral presentation at the World Congress of Veterinary Dermatology.
Received FDA Minor Use/Minor Species (MUMS) Drug Designation, making the program eligible for conditional approval and seven years of exclusive market rights.
Awarded a $500,000 FDA MUMS grant to support a prospective, randomized, placebo‑controlled multi‑site field study evaluating a modified‑release mycophenolate formulation for canine immune‑mediated hemolytic anemia.